Monoclonal antibody treatment has proven to be an effective therapeutic option for COVID-19. Researchers at UPMC and the University of Pittsburgh School of Medicine have reported the health system's experience administering life-saving medication. Their report is published in the scientific journal Open Forum Infectious Diseases.
The report details how the group established the largest and most equitable distribution network for COVID-19 monoclonal antibody infusions across Pennsylvania. Preliminary results in the report confirmed the treatment reduced the likelihood of hospitalization and death in UPMC patients who received it.
"When administered soon after infection, this treatment can help certain people fight the virus and keep them from progressing to serious illness and death," said Ryan Bariola, M.D., Director of the UPMC Community Hospital Antimicrobial Stewardship Efforts (CHASE) Program. He continued, "But administering these infusions comes with logistical challenges, so many health care providers opt not to offer the treatment. UPMC overcame these challenges, and we're dedicated to sharing what we learned with other medical centers, clinicians and the public."
This therapy is most helpful when given early, especially within 10 days of infection in people at the highest risk of complications from COVID-19. The report reveals guidelines for US preparation for increased demand in the future.